This article is available to subscribers. Subscribe now. Already have an account? Sign in

EditorialFree Preview

Monoclonal Antibody Therapy in Parkinson’s Disease — The End?

List of authors.
  • Alan Whone, F.R.C.P., Ph.D.

Parkinson’s disease is increasing in incidence at a faster rate than any other serious neurologic condition.1 Despite multiple agents putatively showing preclinical promise, there is no disease-modifying therapy available for clinical use in this disorder. Indeed, no potential treatment has survived scrutiny in a clinical trial to reach approval by a regulatory body. Several target mechanisms have been identified by which to achieve neuroprotection or neurorestoration of dopaminergic neurons that are at the nexus of Parkinson’s disease. One approach, which engendered much hope, has been the targeting of the pathologically aggregated form of the protein α-synuclein.2 Studies of active immunotherapy . . .

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

Author Affiliations

From Translational Health Sciences, Bristol Medical School, University of Bristol, and the Movement Disorders Group, Bristol Brain Centre, Southmead Hospital, North Bristol NHS Trust — both in Bristol, United Kingdom.